Rights & Society
EMA Panel Backs Six New Medicines for EU Approval
The European Medicines Agency's (EMA) human medicines committee has recommended six new medicines for marketing authorisation across the EU. The recommendations cover treatments for a range of conditions, including certain types of cancer, rare genetic disorders, and infectious diseases. These positive opinions are a key step before the European Commission grants final approval for the medicines to be made available to patients. The list includes several 'orphan medicines' specifically developed for treating rare diseases.
New treatments for cancer and rare diseases are one step closer to reaching EU patients.